Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: IDYA stock price vs VRSN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at VRSN's multiple
Needs VRSN P/S.
Implied fair value · at IDYA's multiple
Needs IDYA P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: IDYA FY 2025 (ended Dec 31, 2025) · VRSN FY 2025 (ended Dec 31, 2025).
Trendline
Eight fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
IDEAYA Biosciences, Inc. · implied price per share
Bear
$0.30
Base
$0.35
Bull
$0.41
VERISIGN INC/CA · implied price per share
Bear
$115.52
Base
$135.91
Bull
$156.30
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.07x
-0.05x
Net debt / EBITDA
Leverage against operating earnings
5.09x
-0.37x
Cash and equivalents
Liquid reserves on the balance sheet
$639.39M
$580.50M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Zentalis Pharmaceuticals, Inc.
IDYA vs ZNTL
Blueprint Medicines Corp
IDYA vs BPMC
Jazz Pharmaceuticals plc
IDYA vs JAZZ
Sarepta Therapeutics, Inc.
IDYA vs SRPT
MICROSOFT CORP
IDYA vs MSFT
AMAZON COM INC
IDYA vs AMZN
Alphabet Inc.
IDYA vs GOOGL
CISCO SYSTEMS, INC.
IDYA vs CSCO
CrowdStrike Holdings, Inc.
IDYA vs CRWD
NetApp, Inc.
IDYA vs NTAP
$70.35M
$100.00M
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe IDYA can convert its extreme revenue growth into sustained positive margins, then holding or accumulating may make sense because the current valuation is only modestly below VRSN-implied level and still within the historical band.
IDYA’s current price of $37.65 is above VRSN-implied price of $35.08, indicating a -6.8% downside on the P/S-based framework. The valuation gap is small and sits within the provided historical band, so the setup is more neutral than clearly mispriced.
Supporting Metrics
